SCHEMBL1622290

SCHEMBL1622290

Cc1cc(F)cc(-c2ccc(C(C)(C)C)cc2)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RXRA P19793 3/20 0.47
RXRB P28702 3/20 0.47
TSHR P16473 1/20 0.46
KIF11 P52732 4/20 0.44
HDAC3 O15379 1/20 0.43
HDAC1 Q13547 1/20 0.43
HDAC2 Q92769 1/20 0.43
HDAC8 Q9BY41 1/20 0.43
HDAC6 Q9UBN7 1/20 0.43
CNR2 P34972 1/20 0.42
AKR1C2 P52895 1/20 0.37
AKR1C1 Q04828 1/20 0.37
RXRG P48443 1/20 0.37
DHODH Q02127 1/20 0.37
TNKS O95271 1/20 0.36
PARP1 P09874 1/20 0.36
TNKS2 Q9H2K2 1/20 0.36
GCGR P47871 1/20 0.36
NPC1 O15118 2/20 0.36
MAPT P10636 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13253728 0.88 KIF11 (0.50) RXRARXRBTSHRKIF11AKR1C2
SCHEMBL26179242 0.88 KIF11 (0.50) RXRARXRBTSHRKIF11AKR1C2
SCHEMBL15110562 0.86 TSHR (0.56) RXRARXRBTSHRKIF11CNR2
SCHEMBL16906613 0.85 KIF11 (0.47) RXRARXRBKIF11HDAC3HDAC1
SCHEMBL13967601 0.82 HDAC3 (0.36) RXRARXRBTSHRKIF11HDAC3
SCHEMBL9288148 0.81 ACHE (0.48) RXRARXRBHDAC3HDAC1HDAC2
SCHEMBL1622079 0.77 RXRA (0.47) RXRARXRBTSHRKIF11CNR2
SCHEMBL15125620 0.77 RXRA (0.51) RXRARXRBTSHRKIF11CNR2
SCHEMBL13624109 0.77 KIF11 (0.56) TSHRKIF11DHODHTNKSPARP1
SCHEMBL24721027 0.77 AKR1C2 (0.41) RXRARXRBTSHRKIF11AKR1C2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8791104-B2 1,4-benzodiazepine-2,5-diones with therapeutic properties THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2014-07-29 US disclosed
US-20130261110-A1 NOVEL 1,4-BENZODIAZEPINE-2,5-DIONES WITH THERAPEUTIC PROPERTIES THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2013-10-03 US disclosed
US-20120088757-A1 NOVEL 1,4-BENZODIAZEPINE-2,5-DIONES WITH THERAPEUTIC PROPERTIES THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2012-04-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130261110-A1 NOVEL 1,4-BENZODIAZEPINE-2,5-DIONES WITH THERAPEUTIC PROPERTIES BAD, GABRA5, GABRB1 RXRA 263/4885RXRB 135/4885TSHR 980/4885
US-20120088757-A1 NOVEL 1,4-BENZODIAZEPINE-2,5-DIONES WITH THERAPEUTIC PROPERTIES BAD, GABRA5, GABRB1 RXRA 263/4885RXRB 135/4885TSHR 980/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.